Safety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in children

Abstract

In an open-label study, 49 children aged 1-12years received oseltamivir (30-75mg once daily depending on bodyweight) for 6weeks for influenza prophylaxis. Seventeen participants reported 22 adverse events (AEs); in three participants, AEs were considered probably drug related (nausea or vomiting). No serious AEs were reported. The tolerability profile was similar to pooled safety data from treatment studies (duration of 5days) in children. © 2012 Blackwell Publishing Ltd.